Tenax Therapeutics, Inc.
TENX
Rank in Stocks
#20256
Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated... Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is progressing TNX-201 (imatinib), a tyrosine kinase inhibitor, designed to treat pulmonary arterial hypertension. Founded in 1967, the organization was initially known as Oxygen Biotherapeutics, Inc. until its rebranding to Tenax Therapeutics, Inc. in September 2014. The company maintains its corporate headquarters in Morrisville, North Carolina.
Share Price
$1.62
Last synced: 2026-11-13
Market Cap
$86.59M
Change (1 day)
0.62%
Change (1 year)
-78.93%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Tenax Therapeutics, Inc. (TENX)
Category
Healthcare
EPS for Tenax Therapeutics, Inc. (TENX)
EPS as of September 2026 TTM: $-1.40
According to Tenax Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-1.40. At the end of 2025 the company had an EPS of $-1.34, a decrease compared to its 2024 EPS of $-1.15.
EPS history for Tenax Therapeutics, Inc. from 2000 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.40 | 4.48% |
| 2025 | $-1.34 | 16.52% |
| 2024 | $-1.15 | -96.30% |
| 2023 | $-31.04 | -94.83% |
| 2022 | $-600.80 | -76.20% |
| 2021 | $-2.52K | 18.79% |
| 2020 | $-2.13K | 7,890.15% |
| 2019 | $-26.60 | -99.64% |
| 2018 | $-7.36K | -26.57% |
| 2017 | $-10.02K | 1,504.03% |
| 2016 | $-624.82 | 211.46% |
| 2015 | $-200.61 | -98.75% |
| 2014 | $-16.04K | 602.64% |
| 2013 | $-2.28K | -98.68% |
| 2012 | $-172.90K | 4,728.69% |
| 2011 | $-3.58K | -98.77% |
| 2010 | $-290.23K | -8.85% |
| 2009 | $-318.41K | 5,485.33% |
| 2008 | $-5.70K | 96.99% |
| 2007 | $-2.89K | -22.22% |
| 2006 | $-3.72K | 45.74% |
| 2005 | $-2.55K | 7.60% |
| 2004 | $-2.37K | -21.28% |
| 2003 | $-3.01K | -36.23% |
| 2002 | $-4.73K | 98.68% |
| 2001 | $-2.38K | -98.86% |
| 2000 | $-209.03K | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $-0.89 | -36.43% |
US
|
|
| $15.66 | -1,218.57% |
US
|
|
| $-7.07 | 405.00% |
US
|
|
| $-5.29 | 277.86% |
AU
|
|
| $12.73 | -1,009.44% |
BE
|
Questions about Tenax Therapeutics, Inc.'s earnings per share (EPS)
What is Tenax Therapeutics, Inc.'s earnings per share (EPS)?
Tenax Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-1.40, as of Sep 2026.
What was Tenax Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Tenax Therapeutics, Inc.'s earnings per share (EPS) was $-1.34, compared with $-1.15 in 2024.
How has Tenax Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Tenax Therapeutics, Inc.'s earnings per share (EPS) was highest in 2024 ($-1.15) and lowest in 2021 ($-2.52K).
How does Tenax Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Tenax Therapeutics, Inc.'s earnings per share (EPS) ($-1.40) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $15.66.